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 Context.—Because of the limited number of available
primary bladder paraganglioma (PBPG) cases, the rates of
succinate dehydrogenase (SDH) mutations and the clini-
copathologic characteristics of SDH-deficient tumors have
not been fully studied.
Objective.—To define the clinicopathologic and molec-
ular characteristics of PBPGs.
Design.—A total of 52 PBPGs were collected retrospec-
tively. SDHA and SDHB immunohistochemical stains were
performed. In cases of SDHB expression loss, mutation
analyses of SDHB, SDHC, and SDHD were performed.
Results.—The clinicopathologic features were analyzed
for 52 cases (M:F ¼ 27:25), with a mean age of 56 years
(range, 22–79 years). Tumor sizes were 0.5 to 8 cm (mean,
2.4 cm). Tumor necrosis was present in 5 of 52 cases
(10%), involvement of muscularis propria in 41 (79%),
and lymphovascular tumor invasion in 6 (12%). During a
mean follow-up period of 41 months (range, 1–161
months), 3 of 52 patients (6%) developed metastases, but
no one died from the disease. Immunohistochemistry for
SDHA and SDHB showed that all cases were SDHA intact.
Among them, 43 cases had intact SDHB, whereas 9 cases
were SDHB deficient. Compared with the SDHB-intact
cases, the SDHB-deficient cases were characterized by
large tumor sizes (4.5 versus 1.9 cm; P , .001), a higher
number of mitoses per 10 high-powered fields (2.6 versus
0.1; P ¼ .002), and frequent lymphovascular tumor
invasion (33% versus 7%; P ¼ .02) and metastases (22%
versus 2%; P¼ .02). Mutational analyses for SDHB, SDHC,
and SDHD were performed in 9 SDHB-deficient cases.
Among them, 6 cases were successfully sequenced and
revealed SDHB mutations only.
Conclusions.—Large tumor size, a higher number of
mitoses, and the presence of lymphovascular tumor invasion
and SDHB mutations suggest malignant paraganglioma.
(Arch Pathol Lab Med. 2017;141:671–677; doi: 10.5858/
arpa.2016-0403-OA)
Paragangliomas (PGs) consist of sympathetic and para-sympathetic neoplasms, depending on tumor location
and catecholamine production. Parasympathetic PGs are
located in the head and neck region, and they usually do not
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produce catecholamines, whereas sympathetic PGs are
located in the sympathetic trunk of the abdomen and
usually produce catecholamines.1 Most PGs are located in
the head and neck (69%), followed by the abdominal
(21.5%) and thoracic (9.5%) areas.2 Paragangliomas can
arise sporadically and in the context of several inherited
tumor syndromes.3 Studies have demonstrated that pheo-
chromocytoma-paraganglioma syndrome is a hereditary
condition frequently associated with PGs caused by germ
line mutations in the SDHB, SDHC, or SDHD genes,
encoding 3 of the 4 subunits of mitochondrial complex II,
the succinate-ubiquinone oxidoreductase (succinate dehy-
drogenase [SDH]). The enzyme SDH is located at the
crossroads between the aerobic electron transport chain and
the tricarboxylic acid cycle.4 In contrast to head and neck
PGs, where the SDHD mutation is the most frequent,
followed by SDHB and SDHC,5,6 the SDHB mutation is more
dominant in thoracoabdominal PGs.6,7 Several previous
reports have indicated that the recurrence rate and degree of
malignancy of PGs are higher in cases of SDHB muta-
tion.7–10 Therefore, detecting SDHB mutations in thoraco-
abdominal PGs is crucial for prognosis, because there are no
reliable histologic characteristics to predict malignancy
reported to date.
It was demonstrated that an absence of SDHB staining in
tumor cells indicates underlying SDH germ line mutations
with high reliability.11 In contrast, a loss of SDHA staining
in tumor cells has been observed only in SDHA muta-
tions.12 Concurrent loss of SDHA and SDHB staining is
encountered in tumors with only SDHA mutations, but a
loss of only SDHB staining is found in tumors with all SDH
mutations, except for the SDHA mutation. Therefore, it is
recommended that SDHA sequencing be performed if a
tumor shows a loss of both SDHA and SDHB stains.
Sequencing of SDHB, SDHC, or SDHD is required if a
tumor shows a loss of SDHB staining and intact SDHA
staining.13
Primary bladder PGs (PBPGs) are extremely rare,
accounting for less than 0.05% of all bladder tumors.14
Because of the limited number of available PBPG cases, the
rates of SDH mutations and clinicopathologic characteristics
of SDH-deficient tumors have not been fully determined.
Herein, we report a retrospective study that was performed
using 52 PBPG cases collected from major institutions in
Korea.
MATERIALS AND METHODS
Pathology and Medical Record Review
A search of pathology databases was performed for PBPGs from
19 institutions—namely, Ewha Womans University Mok-dong
Hospital (Seoul), Samsung Medical Center (Seoul), Ajou University
Hospital (Suwon), Yonsei University Severance Hospital (Seoul),
Korea University Anam Hospital (Seoul), Inje University Haeundae
Paik Hospital (Pusan), Inje University Sanggye Paik Hospital
(Seoul), Seoul National University Hospital (Seoul), Hanyang
University Guri Hospital (Guri), Pusan National University
Hospital (Pusan), Incheon St Mary’s Hospital (Incheon), Kyung
Hee University Medical Center (Seoul), Dankook University
Hospital (Cheonan), Dongguk University Hospital (Gyeonju), Inje
University Busan Paik Hospital (Pusan), Asan Medical Center
(Seoul), Gachon University Gil Medical Center (Incheon), Konyang
University Hospital (Daejeon), Seoul National University Bundang
Hospital (Sungnam), and Seoul St Mary’s Hospital (Seoul)—in
South Korea. After reviewing all available hematoxylin-eosin–
stained slides, either one representative paraffin block from each
case or additional unstained slides from each case were collected
from each institution for further immunohistochemical and SDH
mutational studies. Clinical data for each case included age at
diagnosis, sex, personal tumor history, family tumor history, and
clinical outcome. Pathology data for each case included type of
specimen, tumor location, mitotic count, presence of necrosis,
lymphovascular invasion and proper muscle invasion, and immu-
nohistochemical staining results (when available). The Institutional
Review Board at Ewha Womans University Hospital approved the
study.
Immunohistochemical Analysis
All immunohistochemical stains for SDHA and SDHB were
performed on 4-lm–thick, formalin-fixed, paraffin-embedded
whole-tissue sections provided from 19 institutions after pressure
cooker antigen retrieval (0.001 M citrate buffer; pH 6.0), using
mouse anti-SDHA (1:700 dilution; 40-minute incubation; clone
2E3GC12FB2AE2, Abcam, Cambridge, Massachusetts) and anti-
SDHB (1:100 dilution; 40-minute incubation; clone 21A11AE7,
Abcam) monoclonal antibodies, as previously described.13 One case
of pheochromocytoma with a known SDHB mutation, and one
with a known SDHD mutation, were used as controls for tumors
with loss of SDHB immunohistochemical staining.15,16 For a
negative control used for SDHA antibody, dilution buffer was
used instead of the primary antibody. Expression was evaluated as
‘‘intact’’ when granular cytoplasmic staining was observed in tumor
cells. On the other hand, expression was evaluated as ‘‘deficient’’
when there was a complete absence of granular cytoplasmic
staining in tumor cells along with positive staining in the internal
positive control cells, such as sustentacular or proper muscle cells of
the urinary bladder.
Sequence Analysis
In cases of SDHB expression loss, mutation analyses of SDHB,
SDHC, and SDHD were performed. Genomic DNA was isolated
from the tumor using a QIAamp DNA FFPE tissue kit (Qiagen,
Valencia, California). Tumor DNA was amplified using primers for
exons 8, 6, and 4 of SDHB, SDHC, and SDHD, respectively (primers
used are listed in Table 1). Normal corresponding tissues were not
available. Bidirectional sequencing was performed using the
BigDye Terminator v1.1 kit (Applied Biosystems, Foster City,
California) on an ABI 3130xl genetic analyzer (Applied Biosystems).
Sequencer version 4.10.1 (Gene Codes Corporation, Ann Arbor,
Michigan) was used, along with manual chromatogram reviews for
sequence analysis. Confirmatory resequencing from replicate
polymerase chain reaction (PCR) was performed for sequences
that were ambiguous or deviated from wild-type, so that all
abnormal sequences were confirmed in at least quadruplicate for
replicate amplification reactions. The results were marked as
mutation-positive if a mutation was detected in both the forward
and reverse DNA strands.
RESULTS
Clinicopathologic Characteristics
Clinicopathologic data are summarized in Table 2. The
patient population (N¼ 52) included 27 male (52%) and 25
female (48%) patients, with a mean age of 56 years at
diagnosis (range, 22–79 years). At the time of diagnosis,
patients with SDHB-deficient tumors were relatively youn-
ger than patients with SDHB-intact tumors (means, 43 and
59 years, respectively; P¼ .002). All patients presented with
a single isolated tumor. Tumor sizes were available in 50 of
the 52 cases, including 41 SDHB-intact and 9 SDHB-
deficient cases. The mean tumor size was 2.4 cm, and it was
larger for SDHB-deficient tumors compared with SDHB-
intact tumors (means, 4.5 and 1.9 cm, respectively; P ,
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.001). A nested, zellballen pattern was present in all cases
(Figure 1, A). The mean number of mitoses per 10 high-
power fields was 0.3, and it was higher for SDHB-deficient
tumors compared with SDHB-intact tumors (means, 2.6 and
0.1, respectively; P ¼ .002). One atypical mitosis was
identified in a case of an SDHB-deficient tumor (Figure 1,
B). Of 52 cases, tumor necrosis was present in 5 cases (10%),
proper muscle invasion was present in 41 cases (79%), and
Table 1. Primer Sequences and Polymerase Chain Reaction Conditions for Detection of SDHB, SDHC, and SDHD
Primer Names Forward Primer Sequence Reverse Primer Sequence Ta, 8C
SDHB EX1 GGTCCTCAGTGGATGTAGGC CTTGCCCTATGCTTCCTCAG 58
SDHB EX2 TGGATATTGAATGCCTGCCT GCCTTCCAAGGATGTGAAAA 58
SDHB EX3 ACATCCAGGTGTCTCCGATT CCCACGTACCTTCTCTGCAT 58
SDHB EX4 TGGATATTGAATGCCTGCCT ACAAATCCTGCCCTGAAAAA 58
SDHB EX5 CAGTGTCCAAGAAATGGGGT TGCCAGTTCCTCTCCAGAAT 58
SDHB EX6 GCACTGACCCCAAAGGTAAC ATGGCAATGAAGGAAACCAG 58
SDHB EX7 CCAGAGCTTTGAGTTGAGCC TGGTCCCTTTCCTTCTCAAA 58
SDHB EX8 AACCCCTATGGTTTTGAGGG TGCTGTATTCATGGAAAACCAA 58
SDHC EX1 GTCACATGACACCCCCAAC CCCAGGCACAGGATAAACAG 60
SDHC EX2 TCTATCCCTTCACCCCTAAAAA CGCCTGTAGTCCCAGCTACT 60
SDHC EX3 TTTTCAAACGGTCTGGTTTT TGGTTGAGTAAAAGTGAGGGAAG 62
SDHC EX4 GAGCTGAGATCATGCCATTG TTCAAAGGAGGCGGAGACTA 62
SDHC EX5 CAGGGGTCCCAGTTTTATGT AGTCTCCCCACTCCCTTCAC 58
SDHC EX6 CGCTTTTCTCTAGAATCATGCTG TTCCCAGGCTGGAGATAAGA 58
SDHD EX1 TTCACCCAGCATTTCCTCTT CTGGAGGCTACGCTAAGCAC 58
SDHD EX2 TCAGTCCTGTTAAAGGAGAGGTTC CCCCCTACAGGTAGGAAGTC 58
SDHD EX3 TTTGGGTTACTGTGTGGCATA CACAGCAAACAAACTGAGCA 58
SDHD EX4 TTTTTGCAGCCAAGTTATCTGT CATGACAAAGCAGAGGCAA 58
Abbreviation: Ta, annealing temperature.














Sex, No. (%) .09c
Female 25 (48) 23 (53) 2 (22) 2 (29) 0 (0)
Male 27 (52) 20 (47) 7 (78) 5 (71) 2 (100)
Age at diagnosis, y .002d
Mean 56 59 43 45 36.5
Range 22–79 34–79 22–65 26–65 22–51
Isolated bladder PGL, No. (%)
Yes 52 (100) 43 (100) 9 (100) 7 (100) 2 (100)
No 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Tumor characteristics
Size, cm, mean 2.4 1.9c 4.5 3.7 7.3 ,.001e
Mitoses, mean per 10 HPF 0.3 0.1 2.6 1.1 4 .002f
Necrosis, No. (%) 5 (10) 4 (9) 1 (11) 0 (0) 1 (50) .87c
Lymphovascular invasion, No. (%) 6 (12) 3 (7) 3 (33) 2 (29) 1 (50) .02c
Proper muscle invasion, No. (%) 41 (79) 32 (74) 9 (100) 7 (100) 2 (100) .09c
Metastatic disease, No. (%) .02c
No 49 (94) 42 (98) 7 (78) 7 (100) 0 (0)
Yes 3 (6) 1 (2) 2 (22) 0 (0) 2 (100)
Systemic metastases 2 (4) 1 (2) 1 (11) 0 (0) 1 (100)
Nodal metastases 2 (4) 1 (2) 1 (11) 0 (0) 1 (100)
Family history of PGL
No 52 (100) 43 (100) 9 (100) 7 (100) 2 (100)
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
SDH mutational analysis, No. (%)g
SDHB mutation 6 (100) 4 (100) 2 (100)
SDHB wild type 0 (0) 0 (0) 0 (0)
Abbreviations: HPF, high-power field; PGL, paraganglioma.
a Tumor size was available for 41 of 43 SDHB-intact cases.
b SDHB intact (n ¼ 43) versus SDHB deficient (n ¼ 9).
c Chi-square test.
d By t test.
e Mann-Whitney.
f Fisher exact test.
g SDH mutational analysis was successfully performed in 6 of 9 SDHB-deficient cases.
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lymphovascular invasion (LVI) was present in 6 cases (12%;
Figure 1, C and D). The presence of LVI was found to occur
more frequently in SDHB-deficient cases compared with
SDHB-intact tumors (3 of 9; 33%; and 3 of 43; 7%;
respectively; P ¼ .02). The presence or absence of tumor
necrosis and proper muscle invasion, as well as tumor cell
morphology (polygonal versus spindle), nuclear size, and
nuclear pleomorphism, were not associated with SDHB
status or malignant PGs. Only 3 of 52 patients (6%)
developed metastases during a follow-up period of 41
months (range, 1–161 months): 1 had intact SDHB and 2
were SDHB deficient. A single SDHB-intact patient had
bone and lymph node metastases 3 years after initial
diagnosis, an SDHB-deficient patient had lymph node
metastases at the time of diagnosis, and a second SDHB-
deficient patient had multiple bone metastases 8 years after
the initial diagnosis. None had a family history of PGs.
Comparison of benign and malignant PGs is shown in Table
3. The mean tumor size was 2.4 cm, and it was larger for
malignant PGs compared with benign PGs (means, 6.2 and
2.1 cm, respectively; P¼ .002). Presence of LVI was found to
occur more frequently in malignant PGs compared with
benign PGs (2 of 3; 67%; and 4 of 49; 8%; respectively; P¼
.03).
Results of Immunohistochemical Analyses
SDHA and SDHB immunostaining was performed in all
52 cases, and all showed intact staining for SDHA. Of 52
cases, 9 cases (17.3%) showed a loss of SDHB expression.
The remaining 43 cases (83%) showed intact staining for
both SDHA and SDHB. Representative images of SDHA
and SDHB staining are shown in Figure 2. Homogeneous
cytoplasmic granular staining of SDHA and SDHB was
observed throughout the tumors in all positive cases (Figure
2, A). Loss of SDHB staining was observed uniformly in the
tumor cells, compared with positive staining of the internal
control cells (endothelial, sustentacular, and proper muscle
cells; Figure 2, B).
Results of Sequencing Analyses
Genetic analyses detected SDHB mutations in all 6 SDHB-
deficient tumors that were successfully sequenced. The
results of the sequencing analyses for the 6 cases were as
follows: in the first case, 4 missense mutations were
detected in exons 3 and 8. A heterozygous single–base pair
substitution was found at 2 points of exon 3, c.233 A.G
Figure 1. Examples of SDHB-deficient paragangliomas. A, Hematoxylin-eosin–stained slide. B, Atypical mitosis (arrow). C, Lymphovascular
invasion. D, Lymphovascular invasion highlighted by immunohistochemical staining (original magnification 3200 [A]; hematoxylin-eosin, original
magnifications3400 [B] and3100 [C]; D2-40, original magnification3100 [D]).
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(p.K78R) and c.241 A.G (p.N81D); and at 2 points of exon
8, c.776 C.T (p.P259L) and c.818 A.G (p.Y273S). In the
second case, 2 missense mutations were detected at exon 6,
c.571 T.A (p.C191S) and c.578 G.A (p.S193N). In the third
case, 1 missense mutation was detected at exon 3, c.221
T.C (p.M71T). In the fourth case, 1 silent mutation was
detected at exon 1, c.171C.T (p.T57T). In the fifth case, 1
silent mutation was detected at exon 3, c.225T.C (p.A75A).
In the sixth case, 1 intronic mutation was detected at exon 1,
c.72þ24G.A; and 1 silence mutation at exon 3, c.225T.C
(p.A75A). Features of SDHB-mutated PBPGs are summa-
rized in Table 4.
DISCUSSION
Primary bladder PGs are rare, with an incidence of only
0.67% (2 of 297) of total PGs reported.2 Moreover,
malignant PBPGs in particular are extremely rare, and the
incidence of malignancy is not well known, because the
Table 3. Comparison of Benign and Malignant Paragangliomas of Bladdera
Characteristics Total Cohort (N ¼ 52) Benign PG (n ¼ 49) Malignant PG (n ¼ 3) P
Sex, No. (%)
Female 25 (48) 25 (51) 0 (0) .24b
Male 27 (52) 24 (49) 3 (100)
Age at diagnosis, y .11c
Mean 56 57 41
Range 22–79 26–79 22–51
Isolated bladder PG, No. (%)
Yes 52 (100) 49 (100) 3 (100)
No 0 (0) 0 (0) 0 (0)
Tumor characteristics
Size, cm, mean 2.4 2.1 6.2 .002c
Mitoses, mean per 10 HPF 0.3 0.2 1 .14c
Necrosis, No. (%) 5 (10) 4 (8) 1 (33) .27b
Lymphovascular invasion, No. (%) 6 (12) 4 (8) 2 (67) .03b
Proper muscle invasion, No. (%) 41 (79) 38 (78) 3 (100) ..99b
Family history of PG, No. (%)
No 52 (100) 49 (100) 3 (100)
Yes 0 (0) 0 (0) 0 (0)
SDHB IHC, No. (%) .07b
Intact 43 (83) 42 (86) 1 (33)
Deficient 9 (17.3) 7 (14) 2 (67)
SDHB mutation, No. (%) .003b
Mutation 6 4 2
Not done 46 45 1
Abbreviations: HPF, high-power field; IHC, immunohistochemistry; PG, paraganglioma.
a Tumor size was available for 50 cases (47 benign, 3 malignant).
b Fisher exact test.
c Mann-Whitney.
Figure 2. A, Immunohistochemical staining for SDHA in a paraganglioma with intact expression of SDHB. Staining is cytoplasmic and granular. B,
Immunohistochemical staining for SDHB in a paraganglioma with loss of SDHB expression. Sustentacular cells show positive staining as an internal
positive control (original magnifications3100 [A] and3200 [B]).
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relevant criteria have not been well established. In previous
studies, the incidence of malignancy in PBPGs was from
6.6% to 18% of all PBPGs.13,17,18 Based on World Health
Organization criteria, PGs are defined as malignant only
when metastases are identified at the anatomic sites where
ganglia are normally absent.19 Predicting the malignant
potential is an issue of great interest. Clinicopathologic
characteristics and a scoring system have been suggested to
predict malignant potential in pheochromocytomas of
adrenal glands.20 However, this scoring system has not
been well accepted for PBPGs, and the biologic character-
istics of PGs arising in the bladder may be different from the
pheochromocytoma of the adrenal glands. A total of 37
cases of malignant PBPGs have been previously reported, as
previously summarized by literature review.21 In this review,
malignant tumors occurred more frequently in younger
males, whereas size was not correlated with the likelihood
of metastasis.21 In our study, we have also found that
patients with SDHB-deficient tumors were younger than
patients with SDHB-intact tumors (43 and 59 years,
respectively; P ¼ .002) at the time of diagnosis, but no
preference in sex was identified (P ¼ .09). A recent report
showed a female predilection (8 of 11; 73%).22 In contrast to
the literature review, we found larger sizes of SDHB-
deficient tumors compared with SDHB-intact tumors
(means, 4.5 and 1.9 cm, respectively; P , .001). Our result
is also consistent with the recent report by Gupta et al.22 In
the literature review, metastases in the pelvic lymph nodes
were most common, followed by extrapelvic metastases,
including mediastinum, lung, mesentery, liver, bone, and
peritoneum.21 Regarding our 3 cases, lymph nodes and
bones were the metastatic sites.
We found that mitotic activity was higher for SDHB-
deficient tumors compared with SDHB-intact tumors (2.6
and 0.1 mitoses per 10 high-power fields, respectively; P ¼
.002). This result is consistent with previous research.13 In
our study, mitotic figures were very rare and difficult to find
in SDHB-intact PGs, but occasional mitoses were identified
in SDHB-deficient PGs, with 1 case of an SDHB-deficient
PG exhibiting an atypical mitosis. We also found that the
frequency of LVI was higher for SDHB-deficient tumors
compared with SDHB-intact tumors (33% and 7%, respec-
tively; P ¼ .02). Reliable pathologic criteria have not been
established for malignancy to date. In our study, we did not
definitely identify any morphologic features that could be
useful when predicting malignant PBPGs, because only 3
cases showed evidence of malignancy. However, large tumor
size (6.2 and 2.1 cm, respectively; P¼ .002) and the presence
of LVI (67% and 8%, respectively; P ¼ .03) may be useful
features in predicting aggressive biologic behavior of PBPGs.
SDH mutations have been found in approximately 30% of
both head and neck, and thoracoabdominal PGs,6,7 with
SDHB mutations being detected more frequently in thora-
coabdominal PGs compared with head and neck PGs.6
Although SDHB mutations in PBPGs have been reported,
the rate of SDH mutations in PBPGs has not been
established to date. In 2 recent reports, SDH mutations were
mainly SDHB, although SDHA mutations were also noted.13
In accordance with these studies, our results also demon-
strated that SDHB mutations predominated. SDHB muta-
tions correlated with malignant behavior in both PGs and
pheochromocytomas.7–10 In our study, all 6 SDH-deficient
cases that were successfully sequenced showed SDHB
mutations. Until now, only 2 cases have shown malignant
behavior and 4 exhibited a benign clinical course (Table 4).
Two cases with malignant behavior have been followed up
for an extended period of time (111 and 161 months,
respectively), but 4 cases with indolent behavior have been
followed up for a relatively short period of time, except for 1
case (21, 24, 72, and 120 months, respectively). Therefore,
these 4 SDHB-mutated indolent PGs have to be followed up
for an extended period of time in order to fully confirm
whether they are truly benign or not, because in some cases,
metastases can occur many years after the initial diagnosis.
Our study has several limitations. First, it was a
retrospective, nationwide, multi-institutional study that
evaluated the clinicopathologic characteristics of PBPGs
and, as such, only paraffin-embedded tumor tissues were
available for mutational analyses. This prevented a distinc-
tion between germ line and somatic mutations. However,
cases with SDHB mutations are expected to be mostly germ
line, because it is known that the vast majority of SDH-
deficient PGs harbor germ line SDH mutations, with only
rare reports of somatic SDH mutations.23,24 Moreover, recent
studies have also demonstrated that most cases with SDHB
mutations were germ line.13,25 Second, the follow-up period
was relatively short (a mean of 41 months) compared with
previous studies (means of 70 and 124 months, respective-
ly).13,22 This could explain the lower frequency of malignant
PGs in our study (3 of 52; 5.8%) compared with the previous
studies (2 of 11; 18%; and 5 of 11; 45%; respectively).13,22 In
one particular study, a single case of distant metastasis
developed 10 years after diagnosis.17 Therefore, longer
follow-up periods are recommended to determine the exact












mo SDHB Mutational Status Metastasis
1 56/M 4.6  0  21 4 missense mutations: exon 3, c.233 A.G
(p.K78R) and c.241 A.G (p.N81D); and
exon 8, c.776 C.T (p.P259L) and c.818
A.G (p.Y273S)

2 32/F 4.5  2 þ 24 2 missense mutations: exon 6, c.571 T.A
(p.C191S) and c.578 G.A (p.S193N)

3 22/M 8  3 þ 111 1 missense mutation: exon 3, c.221 T.C
(p.M71T)
þ
4 51/M 6.5  0  161 1 silent mutation: exon 1, c.171C.T (p.T57T) þ
5 35/M 3.5 þ 4  72 1 silent mutation: exon 3, c.225T.C (p.A75A) 
6 65/F 3  0  120 1 intronic mutation: exon 1, c.72þ24G.A; and
1 silent mutation: exon 3, c.225T.C
(p.A75A)

Abbreviations: HPF, high-power field; LVI, lymphovascular invasion;, not present;þ, present.
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frequency of malignant PBPGs. Third, mutational analysis
was not available for 1 SDHB-intact tumor that developed
metastasis. Even though immunohistochemistry for SDHB
provides a sensitive and specific method for identifying
tumors with SDH mutation,10 in this case, the tissue was not
available for mutational analysis to document unequivocal
mutation results. Nonetheless, in our study we used a
relatively large cohort size of 52 cases with PBPGs, which
were collected nationwide from multiple institutions in
Korea; therefore, we believe that this study is representative
of the general clinicopathologic characteristics of PBPGs.
In conclusion, PBPG is a very rare bladder tumor with
17% (9 of 52) incidence of SDH deficiency and 5.8% (3 of
52) incidence of malignancy. Younger age of the patient,
large tumor size, higher number of mitoses, and presence of
LVI and SDHB mutations are potential criteria to predict the
malignant behavior of PBPGs.
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